Pharvaris, N.V (PHVS)
| Market Cap | 951.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.10M |
| Shares Out | 31.84M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $28.75 |
| Previous Close | $33.61 |
| Change ($) | -4.86 |
| Change (%) | -14.46% |
| Day's Open | 34.06 |
| Day's Range | 28.14 - 34.62 |
| Day's Volume | 139,702 |
| 52-Week Range | 23.06 - 42.86 |
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists...
Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volun...
ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercia...
ZUG, Switzerland-- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery,...
Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema.
Pharvaris, a Dutch Phase 1 biotech developing small molecule therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Pharvaris, N.V has filed to go public with an IPO on the NASDAQ.
About PHVS
Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
| Industry Biotechnology | IPO Date Feb 5, 2021 |
| CEO Berndt Modig | Employees 14 |
| Stock Exchange NASDAQ | Ticker Symbol PHVS |